24/7 Market News Snapshot 09 July, 2025 – KALA BIO, Inc. Common Stock (NASDAQ:KALA)

July 9, 2025

DENVER, Colo., 09 July, 2025 (www.247marketnews.com) – (NASDAQ:KALA) are discussed in this article.
KALA BIO, Inc. has recently demonstrated significant market momentum, with shares opening at $5.15 and rising to $5.75, marking an 11.43% increase from the previous closing price of $5.16. This positive movement is accompanied by a trading volume of 792.93K, indicative of growing investor interest. Market analysts are closely observing this upward trend, which could represent a bullish reversal as traders aim to maintain the stock above critical resistance levels, potentially leading to further gains.

In parallel, KALA has reached a pivotal milestone by completing patient enrollment in the CHASE (Corneal Healing After Secretome Therapy) Phase 2b clinical trial. This study evaluates KPI-012, an innovative therapy aimed at treating persistent corneal epithelial defect (PCED). The trial, which is multicenter and randomized, includes 79 patients across 37 sites and aspires to address a pressing unmet medical need for those suffering from this debilitating eye condition.

KPI-012, derived from human mesenchymal stem cell secretome, is designed to enhance corneal healing, which is vital for preserving vision in affected individuals. With no currently approved treatments targeting the diverse underlying factors of PCED, KALA views KPI-012 as a potential game-changer in the field. The primary goal of the trial is to achieve complete healing of PCED, utilizing sophisticated corneal fluorescein staining techniques for evaluation.

Kim Brazzell, Ph.D., Chief Medical Officer of KALA BIO, highlighted the completion of enrollment as a critical step towards offering a solution that may significantly benefit the quality of life for PCED patients. KALA expects to release topline trial results by the end of the third quarter of 2025, which could pave the way for a Biologics License Application (BLA) submission, contingent on favorable outcomes. Additionally, KPI-012 has received Orphan Drug and Fast Track designations from the FDA, showcasing KALA’s dedication to advancing therapeutic options for underserved populations and exploring other possible indications for this promising treatment.

Related news for (KALA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.